Cita APA

Glazar, D., Brady, R., Howard, R., Grass, D., Arrington, J., Yu, M., . . . Enderling, H. (2019). COMP-13. EARLY TUMOR VOLUME EVOLUTION ADAPTIVELY PREDICTS PATIENT-SPECIFIC RESPONSE AND PROGRESSION RISK TO RADIOTHERAPY, PEMBROLIZUMAB, AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA IN A PHASE I TRIAL. Neuro Oncol.

Citación estilo Chicago

Glazar, Daniel, Rene Brady, Rachel Howard, Daniel Grass, John Arrington, Michael Yu, Natarajan Raghunand, Solmaz Sahebjam, y Heiko Enderling. "COMP-13. EARLY TUMOR VOLUME EVOLUTION ADAPTIVELY PREDICTS PATIENT-SPECIFIC RESPONSE AND PROGRESSION RISK TO RADIOTHERAPY, PEMBROLIZUMAB, AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA IN A PHASE I TRIAL." Neuro Oncol 2019.

Cita MLA

Glazar, Daniel, et al. "COMP-13. EARLY TUMOR VOLUME EVOLUTION ADAPTIVELY PREDICTS PATIENT-SPECIFIC RESPONSE AND PROGRESSION RISK TO RADIOTHERAPY, PEMBROLIZUMAB, AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA IN A PHASE I TRIAL." Neuro Oncol 2019.